CAHIERS MAGELLANES-NS
Volume 06 Issue 2
2024

ISSN:1624-1940
DOI 10.6084/m9.figshare.2632599
http://magellanes.com/

ADVANCEMENTS IN GLUCOSE MONITORING: A COMPREHENSIVE SURVEY OF TECHNIQUES AND TECHNOLOGIES

Harshini Manoharan, Sowmya M, Dhilipan J, Saravanan A
[1,2,] Assistant Professor, [3,4] Professor
[1,2,3] Department of Computer Science and Applications,
Faculty of Science and Humanities,
SRM Institute of Science and Technology, Ramapuram, Chennai – 89.
[4] Easwari Engineering College, Ramapuram, Chennai – 89.

ABSTRACT

Advancements in healthcare technology, specifically in Medicare, have led to the development of both invasive and noninvasive bionic devices for monitoring physiological glucose levels. Traditional invasive methods, such as finger pricking, are described, with an emphasis on the discomfort it may cause, especially in specific populations. The paragraph details the mechanics of finger-pricking tools, highlighting single-use and multi-use devices. The challenges of the conventional finger-pricking method, particularly its painful nature, paves way for the exploration of painless non-invasive glucose monitoring techniques. Non-invasive methods were designed to minimize discomfort and enable continuous glucose monitoring providing real time data. This chapter underscores the significance of continuous monitoring for effective diabetes management. The chapter also addresses the limitations of continuous glucose monitoring, such as potential inaccuracies in subcutaneous glucose concentration readings that could impact insulin infusion rates, leading to hypoglycemia or hyperglycemia. It notes that existing studies primarily focus on improving the performance and accuracy of continuous glucose monitoring devices, with limited attention to meta-analysis, analyte types for glucose sensing, diabetes types, and the analysis of glucose concentration trends and patterns. This chapter also provides a comprehensive review of top commercialized continuous glucose monitoring systems in the market, offering insights into their role in glycemic control and diabetes management.

Keywords – Diabetes Mellitus, Glucose, Glucose Monitoring System, Invasive, Non-Invasive.

I. INTRODUCTION

In the healthcare industry, machine learning is becoming increasingly important as it aids in various aspects of patient care, diagnosis, treatment planning, and overall healthcare administration. Machine Learning algorithms can analyze large datasets to identify trends and predict the probable incidence of the diseases. This is particularly beneficial for risk stratification, assisting medical professionals in identifying patients more likely to experience problems and devising preventive strategies accordingly. By analyzing genetics, patient data, and other variables, machine learning

ISSN:1624-1940
DOI 10.6084/m9.figshare.2632599
http://magellanes.com/

contributes to the advancement of personalized medicine, customizing treatment regimens based on individual traits. This approach reduces the possibility of side effects while enhancing therapeutic efficacy. The following are some ways in which machine learning assists in diabetes management:

- Glucose Monitoring and Prediction
- Insulin Dosage Optimization
- Early Detection of Complications
- Automated Insulin Delivery
- Personalized Treatments
- Behavioral Analytics for Lifestyle Modifications

Healthcare practitioners can transition to more proactive and individualized care by using machine learning to predict diabetes complications, aiming to prevent or alleviate the burden of complications on diabetics. Nevertheless, it is imperative to integrate these models into the clinical workflow and evaluate the predictions they make considering the unique needs and preferences of each patient.

II. LITERATURE SURVEY

Kaufman et al. [1] discusses the role of CGM systems specifically in pediatric patients. Chase et al.'s study [2] focuses on continuous subcutaneous glucose monitoring in children with type 1 diabetes. The inclusion of a patent by Joseph et al. [3] reflects technological advancements in glucose monitoring systems. Gilligan et al. [4] evaluate a subcutaneous glucose sensor over three months in a dog model. [5-7] provide an overview of continuous glucose monitoring systems for type 1 diabetes. The JDRF Continuous Glucose Monitoring Study Group contributes significant findings regarding the effectiveness and clinical care environment impact of CGM. Liebl et al. [8] offer evidence and consensus statements for the clinical use of continuous glucose monitoring.

Price et al. [9] engage in a discussion on the appropriateness of systematic reviews and meta-analyses for assessing evolving medical device technologies. Forlenza et al. [10] analyze the ambulatory glucose profile of the JDRF CGM dataset in pediatric diabetes. El-Laboudi et al. [11] explore measures of glycemic variability in type 1 diabetes and the influence of real-time continuous glucose monitoring. Rodbard D [12] delves into hypo- and hyperglycemia in relation to various statistical measures of glucose distribution. Dunn et al. [13] present the Likelihood of Low Glucose (LLG) algorithm for assessing the risk of hypoglycemia. Clinical practice guidelines from Klonoff et al. [14] and Peters et al. [15] highlight the importance of CGM in diabetes management. NICE guidelines [16] provide recommendations for the diagnosis and management of type 1 diabetes in adults. ISPAD guidelines [17] focus on the assessment and monitoring of glycemic control in children and

ISSN:1624-1940
DOI 10.6084/m9.figshare.2632599
http://magellanes.com/

adolescents with diabetes. Fonseca et al. [18] present a consensus conference on continuous glucose monitoring.

The American Diabetes Association's [19] Standards of Medical Care in Diabetes summarize revisions to care standards. Damiano et al. [20] conduct a comparative effectiveness analysis of three continuous glucose monitors. Yan Yao et al. [25] contribute a meta-analysis on subcutaneous continuous glucose monitoring in critically ill patients during insulin therapy. Federico Ribet et al. [26] discuss real-time intradermal continuous glucose monitoring using a minimally invasive microneedle-based system. Rice and Coursin [27] address facts and challenges associated with continuous glucose measurement. Marc Parrilla et al. [28] explore wearable hollow micro-needle sensing patches for transdermal electrochemical monitoring of glucose. Lastly, investigations by Whitmer [29], Schwartz et al. [30], and McCoy et al. [31] probe the relationships between type 2 diabetes, cognitive impairment, falls in older adults, and increased mortality associated with severe hypoglycemia, respectively. Geller et al. [32] provide national estimates of insulin-related hypoglycemia and errors leading to emergency department visits and hospitalizations. This comprehensive survey underscores the evolution, applications, and critical considerations associated with continuous glucose monitoring in diverse medical contexts. The development of glucose monitoring devices has been a dynamic and revolutionary process, propelled by technological breakthroughs and an increased comprehension of diabetes care. Future innovations in diabetes management tools are being shaped by ongoing research and technology advancements.

III. CONVENTIONAL METHODS FOR DIABETES PREDICTION

Traditional approaches for predicting diabetes involve various methods that have been widely used over the years. A comparative study of the various glucose monitoring techniques is illustrated in Table 3.1. These conventional methods typically rely on risk factors and clinical indicators to assess an individual's likelihood of developing diabetes. Here are some common conventional methods for diabetes prediction:

a) Fasting Blood Sugar Test (FBS) - This test measures the blood glucose level after an overnight fast. Elevated fasting blood sugar levels may indicate insulin resistance or early-stage diabetes.

b) Oral Glucose Tolerance Test (OGTT) - This test involves fasting overnight, followed by drinking a glucose solution, and then measuring blood sugar levels at intervals. It helps diagnose diabetes and prediabetes.

CAHIERS MAGELLANES-NS
Volume 06 Issue 2
2024

ISSN:1624-1940
DOI 10.6084/m9.figshare.2632599
http://magellanes.com/

c) Glycated Hemoglobin (HbA1c) Test - This blood test provides an average of blood sugar levels over the past two to three months. Elevated HbA1c levels indicate poor blood sugar control and may suggest a risk of diabetes.

d) Body Mass Index (BMI) - Obesity is a significant risk factor for T2DM. BMI, calculated using height and weight, is used to assess whether an individual is underweight, normal weight, overweight, or obese.

e) Family History Assessment - Individuals with a family history of diabetes are at a higher risk. Considering the family's medical history helps in identifying genetic predispositions.

f) Age and Gender - Advancing age is a risk factor for diabetes, and men may have a higher risk than women, although the risk for women increases with conditions like gestational diabetes.

It's important to note that while these conventional methods are valuable, advancements in technology and research have also led to the development of more sophisticated predictive models and risk assessment tools for diabetes. These may incorporate genetic factors, biomarkers, and artificial intelligence for more accurate predictions.

Table 3.1 Comparison on Glucose Monitoring Techniques

Factors	Invasive	Non-Invasive	Minimally Invasive
Invasiveness [31]	Penetrates the body's natural barriers.	Does not penetrate the body's surface.	Involves minimal penetration with small incisions or entry points.
Risk and Complications	Higher risk of complications, including infections and longer recovery times.	Lower risk of complications, generally quicker recovery.	Intermediate risk, with reduced complications compared to invasive procedures.
Precision and Complexity	Offers high precision and allows for complex procedures.	Limited in complexity but suitable for various diagnostic purposes.	Allows for a range of moderately complex procedures with reduced invasiveness.
Recovery Time	Longer recovery times.	Shorter recovery times.	Intermediate recovery times, often shorter than invasive procedures.

CAHIERS MAGELLANES-NS
Volume 06 Issue 2
2024

ISSN:1624-1940
DOI 10.6084/m9.figshare.2632599
http://magellanes.com/

3.1 Invasive Glucose Monitoring Techniques

a) Hexokinase Method for Glucose Determination - Bondar et al. [33] conducted an evaluation of glucose-6-phosphate dehydrogenase from Leuconostoc mesenteroides in the hexokinase method for determining glucose in serum. Their work in clinical chemistry during 1974 laid the foundation for understanding the enzymatic processes involved in glucose measurement, contributing significantly to diagnostic methodologies.

b) Finger Prick Blood Monitoring - Finger prick blood monitoring has been a traditional method for assessing blood glucose levels. Bond et al. [34] explored drop-to-drop variation in the cellular components of finger prick blood, highlighting implications for point-of-care diagnostic development. This research is instrumental in understanding the reliability and consistency of finger prick blood samples.

c) Non-Invasive Glucose Monitoring - Amaral et al. [35] delve into the current developments in non-invasive glucose monitoring. Their work in medical engineering and physics contributes to the exploration of alternative methods that reduce the invasiveness of glucose monitoring, offering potential improvements in patient comfort and compliance.

d) Smart Insulin Prediction System - Obeidat et al. [36] present a system for blood glucose monitoring and smart insulin prediction. This innovative approach, published in the IEEE Sensors Journal, signifies advancements in technology aiming to enhance the precision and predictability of insulin dosing based on real-time blood glucose data. Such systems hold promise for optimizing diabetes management strategies. Table 3.2 highlights the various Invasive glucose monitoring techniques.

Table 3.2 Summary study of Invasive Glucose Monitoring Techniques

Technique	Description	Advantages	Disadvantages
Fingerstick	Blood sample taken from the finger	Quick and easy to perform	Requires blood sample and can be painful
Intravenous (IV)	Blood sample taken from a vein	Accurate and reliable measurements	Invasive procedure, requires healthcare setting
Subcutaneous (SC)	Glucose sensor placed under the skin	Continuous monitoring possible	Invasive procedure, risk of infection
Implanted	Glucose sensor implanted under the skin	Long-term monitoring, accurate measurements	Invasive procedure, risk of complications

ISSN:1624-1940
DOI 10.6084/m9.figshare.2632599
http://magellanes.com/

3.2 Non-Invasive Glucose Monitoring Techniques

a) Spectroscopic Approaches - Khalil, O.S et al. [37] contributed a significant study on the spectroscopic and clinical aspects of noninvasive glucose measurements in 1999. This research delves into the utilization of spectroscopy for glucose measurement, exploring its clinical implications. Spectroscopic techniques, such as near-infrared spectroscopy, are discussed for their potential in noninvasive glucose monitoring.

b) Surface Plasmon Resonance-Based Biosensor - Omidniaee A et al. [38] presented research on a surface plasmon resonance-based SiO2 Kretschmann configuration biosensor for detecting blood glucose. This study explores the application of advanced biosensor technologies, specifically surface plasmon resonance, for noninvasive glucose detection. The focus is on the development of a biosensor using SiO2 in a Kretschmann configuration.

c) Photoacoustic Noninvasive Glucose Testing - MacKenzie H.A et al. [39] presented research on advances in photoacoustic noninvasive glucose testing. This study explores the use of photoacoustic techniques for glucose monitoring. The focus is on noninvasive methods that leverage the photoacoustic effect to detect glucose levels, providing insights into the technological advancements in this area.

d) Dielectric Properties of Polar Molecules - Debye, P.J.W et al. [40] contributed to the foundational understanding of polar molecules in "Polar Molecules." This work is essential for understanding the principles behind the interaction of polar molecules, a key aspect in many noninvasive glucose measurement technologies.

e) Dispersion and Absorption in Dielectrics - Cole, K.S et al. [41] explored the dispersion and absorption in dielectrics in their work "Dispersion and Absorption in Dielectrics I." This foundational research contributes to the understanding of dielectric properties, which is crucial for the development of noninvasive techniques based on alternating current characteristics. Table 3.3 highlights the summarized study on Non-Invasive Glucose Monitoring Techniques.

Table 3.3 Summarized study on Non-Invasive Glucose Monitoring Techniques

Techniques	Accuracy	Continuous Monitoring	Sensor Lifespan	Invasiveness	Calibration	Professional Insertion	Complications	Availability	Cost

ISSN:1624-1940
DOI 10.6084/m9.figshare.2632599
http://magellanes.com/

Optical Sensing	Moderate	No	Short	Non-invasive	Yes	No	Low	Widely	Moderate
Transdermal Sensing	Moderate	No	Short	Non-invasive	Yes	No	Low	Limited	High
Saliva Glucose Testing	Low	No	Short	Non-invasive	No	No	Low	Limited	Low
Breath Acetone Analysis	Low to Moderate	No	Short	Non-invasive	No	No	Low	Limited	High
Sweat Glucose Testing	Good	Yes	Short	Non-invasive	Yes	No	Low	Widely	Low

3.3 Minimally Invasive Continuous Glucose Monitoring Techniques

The significance of effective diabetes management is underscored by its association with cardiovascular diseases, particularly in individuals with T2DM. Laakso et al. [42] highlight the critical link between hyperglycemia and cardiovascular disease, emphasizing the need for advanced monitoring and management strategies.

a) Technological Advancements in Continuous Glucose Monitoring - Cappon et al. [43] provide a comprehensive review of continuous glucose monitoring sensors, presenting a detailed analysis of various technologies and their applications in diabetes management. This review serves as a foundation for understanding the evolving landscape of CGM systems.

b) Overview of CGM Technologies - The evolution of CGM technologies is evident in the Dexcom et al. [44], the FreeStyle Libre CGM (Libre et al. CGM, 2022 [45]), and the Eversense et al. [46] CGM (Eversense CGM, 2022). These technologies offer insights into the diverse approaches taken by manufacturers to enhance glucose monitoring and improve patient outcomes.

c) Skin Integrity and Device Use in Diabetes - Messer et al. [47] delve into the challenges

CAHIERS MAGELLANES-NS
Volume 06 Issue 2
2024

ISSN:1624-1940
DOI 10.6084/m9.figshare.2632599
http://magellanes.com/

associated with preserving skin integrity during chronic device use in diabetes. They discuss potential complications and the importance of addressing skin-related issues to ensure the efficacy of CGM systems.

d) Impact of Technology-Related Skin Problems - Christensen et al. [48] explore the association between skin problems arising from diabetes treatment technology and increased disease burden in adults with t1dm. Understanding these implications is crucial for optimizing the use of CGM devices and minimizing adverse effects.

Table 3.4 Summarized Study on Minimally Invasive Glucose Monitoring Techniques

Technique	Advantages	Disadvantages
Subcutaneous CGM [20]	Non-invasive placement Continuous glucose measurements Easy to use and maintain Widely available and affordable Suitable for long-term use	May cause skin irritation or discomfort Limited accuracy compared to invasive techniques Delayed response time Calibration required Limited lifespan of sensor
Intradermal CGM [21]	Higher accuracy compared to subcutaneous CGM Continuous glucose measurements Lower risk of skin irritation Longer sensor lifespan compared to subcutaneous CGM Suitable for long-term use	More invasive than subcutaneous CGM May cause pain or discomfort during insertion Calibration required Limited availability and higher cost Requires professional insertion
Transdermal CGM [22]	Completely non-invasive No pain or discomfort during use Continuous glucose measurements Easy to use and maintain Suitable for short-term or intermittent monitoring	Less accurate than subcutaneous and intradermal CGM Delayed response time Limited availability and higher cost Calibration required Limited lifespan of sensor

ISSN:1624-1940
DOI 10.6084/m9.figshare.2632599
http://magellanes.com/

Technique	Advantages	Disadvantages
Wearable Patch CGM [25]	Non-invasive placement Continuous glucose measurements Easy to use and maintain Suitable for long-term use Widely available and affordable	Limited accuracy compared to invasive techniques May cause skin irritation or discomfort Delayed response time Calibration required Limited lifespan of sensor

IV. DRAWBACKS OF THE EXISTING SYSTEM

a) Integration of Multi-Omics Data - The integration of diverse data types, such as genomics, metabolomics, and proteomics, could provide a more comprehensive understanding of diabetes risk factors. There is a need for research that explores the synergies among these different omics data to enhance prediction accuracy.

b) Explanatory Models for Risk Factors - While predictive models are effective, there is a research gap in developing explanatory models that provide insights into the specific risk factors contributing to an individual's diabetes risk. Understanding the drivers of predictions could inform targeted interventions.

c) Risk Prediction in Pediatric Populations - Much of the existing research focuses on diabetes prediction in adults. There is a research gap in developing and validating predictive models specifically tailored to pediatric populations, considering the unique physiological and lifestyle factors in children.

d) Personalized Risk Prediction - The current state of the art in diabetes prediction often provides generalized risk assessments. There is a need for research that focuses on personalized risk prediction, considering individual variability in genetics, lifestyle, and environmental factors.

V. CONCLUSION

The literature review on diabetes management provides a multifaceted understanding of the challenges, advancements, and innovations in the field. The diverse array of studies collectively paints a comprehensive picture of the current landscape, emphasizing the importance of personalized and holistic approaches to diabetes care.

ISSN:1624-1940
DOI 10.6084/m9.figshare.2632599
http://magellanes.com/

The integration of continuous glucose monitoring (CGM) technologies emerges as a pivotal aspect of modern diabetes management. From the evaluation of specific CGM devices to the exploration of their impact on different demographic groups, the literature underscores the dynamic nature of these technologies in enhancing real-time monitoring and intervention strategies. However, adoption barriers, especially among adolescents, and the significance of preserving skin integrity during chronic device use highlight the nuanced challenges that must be addressed for widespread acceptance and long-term usability.

REFERENCES

[1] Kaufman FR: Role of the continuous glucose monitoring system in pediatric patients. Diabetes Technol Ther 2000;2(Suppl.1): S49–S52.

[2] Chase HP, Kim LM, Owen SL, et al.: Continuous subcutaneous glucose monitoring in children with type 1 diabetes. Pediatrics 2001; 107:222–226.

[3] Joseph H, Orville RS, David IR, et al.: Glucose monitoring system, US Patent US5497772A. (accessed January8, 2017)

[4] Gilligan BJ, Shults MC, Rhodes RK, Updike SJ: Evaluation of a subcutaneous glucose sensor out to 3 months in a dog model. Diabetes Care 1994;17(8):882–887.

[5] Langendam M, Luijf YM, Hooft L, et al.: Continuous glucose monitoring systems for type 1 diabetes mellitus. Cochrane Database Syst Rev 2012;1:CD008101.

[6] Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group, Tamborlane WV, Beck RW, et al.: Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med 2008; 359:1464–1476.

[7] Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group: Effectiveness of continuous glucose monitoring in a clinical care environment: evidence from the Juvenile Diabetes Research Foundation continuous glucose monitoring (JDRF-CGM) trial. Diabetes Care 2010; 33:17–22

[8] Liebl A, Henrichs HR, Heinemann L, et al.: Continuous glucose monitoring: evidence and consensus statement for clinical use. J Diabetes Sci Technol 2013; 7:500–519.

[9] Price D, Graham C, Parkin CG, Peyser TA: Are systematic reviews and meta-analyses appropriate tools for assessing evolving medical device technologies? J Diabetes Sci Technol 2016; 10:439–446.

[10] Forlenza GP, Pyle LL, Maahs DM, Dunn TC: Ambulatory glucose profile analysis of the juvenile diabetes research foundation continuous glucose monitoring dataset - Applications to

ISSN:1624-1940
DOI 10.6084/m9.figshare.2632599
http://magellanes.com/

the pediatric diabetes population. Pediatr Diabetes 2016. [Epub ahead of print]; DOI: 10.1111/pedi.12474.

[11] El-Laboudi AH, Godsland IF, Johnston DG, Oliver NS: Measures of glycemic variability in type 1 diabetes and the effect of real-time continuous glucose monitoring. Diabetes Technol Ther 2016; 18:806–812.

[12] Rodbard D: Hypo- and hyperglycemia in relation to the mean, standard deviation, coefficient of variation, and nature of the glucose distribution. Diabetes Technol Ther 2012; 14:868–876.

[13] Dunn TC, Hayter GA, Doniger KJ, Wolpert HA: Development of the Likelihood of Low Glucose (LLG) algorithm for evaluating risk of hypoglycemia: a new approach for using continuous glucose data to guide therapeutic decision making. J Diabetes Sci Technol 2014; 8:720–730.

[14] Klonoff DC, Buckingham B, Christiansen JS, et al.: Continuous glucose monitoring: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2011; 96:2968–2979.

[15] Peters AL, Ahmann AJ, Battelino T, et al.: Diabetes technology - continuous subcutaneous insulin infusion therapy and continuous glucose monitoring in adults: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2016; 101:3922–3937.

[16] National Institute for Health and Care Excellence (NICE): NICE Guideline (NG) 17, Type 1 diabetes in adults: diagnosis and management. August 2015. Last updated: July 2016. (cf. pages 25–26, sections 1.6.21–1.6.24). (accessed May3, 2017)

[17] Rewers MJ, Pillay K, de Beaufort C, et al.: Assessment and monitoring of glycemic control in children and adolescents with diabetes. ISPAD Clinical Practice Consensus Guidelines 2014 Compendium. Pediatric Diabetes 2014;15(Suppl.20):102–114.

[18] Fonseca VA, Grunberger G, Anhalt H, et al.: Continuous Glucose Monitoring: A Consensus Conference of The American Association of Clinical Endocrinologists and American College of Endocrinology. Endocr Pract 2016; 22:1008–1021.

[19] [American Diabetes Association: 2017 Standards of Medical Care in Diabetes. Standards of Medical Care in Diabetes—2017: Summary of Revisions. Diabetes Care 2017;40(Suppl.1): S4–S5.

[20] Damiano ER, El-Khatib FH, Zheng H, et al.: A comparative effectiveness analysis of three continuous glucose monitors. Diabetes Care 2013; 36:251–259.

[21] Yan Yao,1, Yi-He Zhao,1,Wen-He Zheng, and Hui-Bin Huang1,Subcutaneous continuous glucose monitoring in critically ill patients during insulin therapy: a meta-analysis,American journal of translation Research, 2022; 14(7): 4757–4767.

ISSN:1624-1940
DOI 10.6084/m9.figshare.2632599
http://magellanes.com/

[22] Federico Ribet , Göran Stemme , Niclas Roxhed , Real-time intradermal continuous glucose monitoring using a minimally invasive microneedle-based system, 2018 Dec 6;20(4):101,doi: 10.1007/s10544-018-0349-6.

[23] Rice MJ, Coursin DB. Continuous measurement of glucose: facts and challenges. *Anesthesiology*. 2012;116(1):199-204.

[24] Marc Parrilla a b, Usanee Detamornrat c, Juan Domínguez-Robles c, Ryan F. Donnelly c, Karolien De Wael a b Wearable hollow micro needle sensing patches for the transdermal electrochemical monitoring of glucose, Volume 249, 1 November 2022, 123695.

[25] Yan Yao,1, Yi-He Zhao,1,Wen-He Zheng, and Hui-Bin Huang1,Subcutaneous continuous glucose monitoring in critically ill patients during insulin therapy: a meta-analysis,American journal of translation Research, 2022; 14(7): 4757–4767.

[26] Federico Ribet , Göran Stemme , Niclas Roxhed , Real-time intradermal continuous glucose monitoring using a minimally invasive microneedle-based system, 2018 Dec 6;20(4):101,doi: 10.1007/s10544-018-0349-6.

[27] Rice MJ, Coursin DB. Continuous measurement of glucose: facts and challenges. Anesthesiology. 2012;116(1):199-204.

[28] Marc Parrilla a b, Usanee Detamornrat c, Juan Domínguez-Robles c, Ryan F. Donnelly c, Karolien De Wael a b Wearable hollow micro needle sensing patches for the transdermal electrochemical monitoring of glucose, Volume 249, 1 November 2022, 123695.

[29] Whitmer, R.A. Type 2 diabetes and risk of cognitive impairment and dementia. Curr. Neurol. Neurosci. 2007, 7, 373–380.

[30] Schwartz, A.V.; Vittinghoff, E.; Sellmeyer, D.E.; Feingold, K.R.; de Rekeneire, N.; Strotmeyer, E.S.; Shorr, R.I.; Vinik, A.I.; Odden, M.C.; Park, S.W.; et al. Diabetes-related complications, glycemic control, and falls in older adults. Diabetes Care 2008, 33, 391–396.

[31] McCoy, R.G.; Houten, H.K.V.; Ziegenfuss, J.Y.; Shah, N.D.; Wermers, R.A.; Smith, S.A. Increased mortality of patients with diabetes reporting severe hypoglycemia. Diabetes Care 2012, 35, 1897–1901. [CrossRef]

[32] Geller, A.I.; Shehab, N.; Lovegrove, M.C.; Kegler, S.R.; Weidenbach, K.N.; Ryan, G.J.; Budnitz, D.S. National estimates of insulin-related hypoglycemia and errors leading to emergency department visits and hospitalizations. JAMA Intern. Med. 2010, 174, 678–686.

ISSN:1624-1940
DOI 10.6084/m9.figshare.2632599
http://magellanes.com/

[33] Bondar, J.L.; Mead, D.C. Evaluation of glucose-6-phosphate dehydrogenase from Leuconostoc mesenteroides in the hexokinase method for determining glucose in serum. Clin. Chem. 1974, 20, 586–590.

[34] Bond, M.M.; Richards-Kortum, R.R. Drop-to-Drop Variation in the Cellular Components of Fingerprick Blood: Implications for Point-of-Care Diagnostic Development. Am. J. Clin. Pathol. 2015, 144, 885–894. [CrossRef] [PubMed]

[35] Amaral, C.E.F.; Wolf, B. Current Development in Non-Invasive Glucose Monitoring. Med. Eng. Phys. 2008, 30, 541–549. [CrossRef] [PubMed]

[36] Obeidat, Y.; Ammar, A. A System for Blood Glucose Monitoring and Smart Insulin Prediction. IEEE Sens. J. 2021, 21, 13895–13909.

[37] Khalil, O.S. Spectroscopic and Clinical Aspects of Noninvasive Glucose Measurements. Clin. Chem. 1999, 45, 165–177. [CrossRef]

[38] Omidniaee, A.; Karimi, S.; Farmani, A. Surface Plasmon Resonance-Based SiO2 Kretschmann Configuration Biosensor for the Detection of Blood Glucose. Silicon 2021, 14, 3081–3090. [CrossRef] Biosensors 2022, 12, 965 16 of 20

[39] MacKenzie, H.A.; Ashton, H.S.; Spiers, S.; Shen, Y.; Freeborn, S.S.; Hannigan, J.; Lindberg, J.; Rae, P. Advances in Photoacoustic Noninvasive Glucose Testing. Clin. Chem. 1999, 45, 1587–1595. [CrossRef]

[40] Debye, P.J.W. Polar Molecules; Dover Publications: Mineola, NY, USA, 1960.

[41] Cole, K.S.; Cole, R.H. Dispersion and Absorption in Dielectrics I. Alternating Current Characteristics. J. Chem. Phys. 1941, 9, 341–351. [CrossRef]

[42] Laakso, M. Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes 1999, 48, 937–942. [CrossRef]

[43] Cappon, G.; Vettoretti, M.; Sparacino, G.; Facchinetti, A. Continuous glucose monitoring sensors for diabetes management: A review of technologies and applications. Diabetes Metab. J. 2019, 43, 383–397. [CrossRef]

[44] Dexom CGM. Available online: https://www.dexcom.com/g6/how-it-works (accessed on 19 March 2022).

[45] Libre CGM. Available online: https://www.freestylelibre.us/cgm-difference/benefits-of-cgm.html (accessed on 19 March 2022).

CAHIERS MAGELLANES-NS
Volume 06 Issue 2
2024

ISSN:1624-1940
DOI 10.6084/m9.figshare.2632599
http://magellanes.com/

[46] Eversense CGM. Available online: https://www.eversensediabetes.com/why-eversense-cgm .

[47] Messer, L.H.; Berget, C.; Beatson, C.; Polsky, S.; Forlenza, G.P. Preserving skin integrity with chronic device use in diabetes. Diabetes Technol. Ther. 2018, 20, S2-54–S2-64.

[48] Christensen, M.O.; Berg, A.K.; Rytter, K.; Hommel, E.; Thyssen, J.P.; Svensson, J.; Nørgaard, K. Skin problems due to treatment with technology are associated with increased disease burden among adults with type 1 diabetes. Diabetes Technol. Ther. 2019, 21, 215–221.